| Literature DB >> 30683149 |
Livia Akemi Ramos Takahashi1, Francisco Winter Dos Santos Figueiredo2, Jucemar Benedet3, Francisco de Assis Guedes de Vasconcelos3, Fernando Adami2.
Abstract
OBJECTIVES: To determine the influence of sexual maturation status on adiposity indicators of children and adolescents.Entities:
Keywords: Adiposity; Obesity; Sexual maturation
Mesh:
Year: 2019 PMID: 30683149 PMCID: PMC6347827 DOI: 10.1186/s13104-019-4095-5
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Characteristics of children and adolescents aged 8 to 14 years
| Variables studied | Boys (n = 1285) | Girls (n = 1408) | P |
|---|---|---|---|
| Number of participants (CI 95%) | |||
| Child’s overweightb | 448 (402–496) | 352 (308–460) | < 0.001 |
|
| 0.940 | ||
| Precocious | 425 (375–478) | 458 (403–517) | |
| Late | 413 (364–469) | 460 (425–498) | |
| Overweight motherb | 388 (301–487) | 456 (398–518) | 0.368 |
|
| < 0.001 | ||
| < 2500 | 71 (46–105) | 118 (100–141) | |
| > 4000 | 190 (166–218) | 110 (77–142) | |
aRao-Scott test for qualitative variables
bMann–Whitney test for quantitative variables
Fig. 1Correlation between age and body adiposity indicators in boys. Β: slope of interquartile regression
Influence of sexual maturation status on adiposity indicators in Brazilian children
| Indicators of adiposity | Precocious | Normal | Late | |||
|---|---|---|---|---|---|---|
| β (CI 95%) | P* | β (CI 95%) | P* | β (CI 95%) | P* | |
|
| ||||||
| Triceps skinfold | 0.1 (− 0.1; 0.2) | 0.29 | 0.03 (− 0.1; 0.1) | 0.62 | 0.1 (− 0.1; 0.3) | 0.26 |
| Arm circumference | 0.46 (− 0.13; 1.05) | 0.129 | 0.07 (− 0.43; 0.56) | 0.792 | − 0.78 (− 1.39; − 0.16) | 0.014 |
| Calf skinfold | − 0.01 (− 0.41; 0.39) | 0.963 | 0.90 (− 0.17; 1.97) | 0.099 | − 0.92 (− 2.08; 0.24) | 0.120 |
| Sum of skin folds | 1.3 (0.7; 1.8) | < 0.001 | 1.1 (0.6; 1.6) | 0.001 | 1.5 (0.6; 2.3) | 0.003 |
|
| ||||||
| Triceps skinfold | 1.71 (1.12; 2.31) | < 0.001 | − 0.08 (− 0.85; 0.69) | 0.837 | − 2.02 (− 2.82; − 1.22) | < 0.001 |
| Arm circumference | 1.17 (0.78; 1.55) | < 0.001 | − 0.30 (− 0.67; 0.07) | 0.107 | − 1.20 (− 1.57; − 0.83) | < 0.001 |
| Calf skinfold | 1.57 (0.78; 2.37) | < 0.001 | 0.078 (− 0.80; 0.95) | 0.861 | − 2.43 (− 3.34; − 1.53) | < 0.001 |
| Sum of skin folds | 6.55 (4.62; 8.48) | < 0.001 | − 1.53 (− 4.46; 1.40) | 0.305 | − 8.20 (− 11.58; − 4.82) | < 0.001 |
* Age-adjusted interquartile regression
STROBE statement—checklist of items that should be included in reports of cross-sectional studies [32]
| Item no. | Recommendation | Pages | |
|---|---|---|---|
| Title and abstract | 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract | 2 |
| (b) Provide in the abstract an informative and balanced summary of what was done and what was found | 2 | ||
|
| |||
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 3 |
| Objectives | 3 | State specific objectives, including any pre-specified hypotheses | 3 |
|
| |||
| Study design | 4 | Present key elements of study design early in the paper | 4 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 4 |
| Participants | 6 | (a) Give the eligibility criteria and the sources and methods of selection of participants | 4 |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 4–5 |
| Data sources/measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 5 |
| Bias | 9 | Describe any efforts to address potential sources of bias | – |
| Study size | 10 | Explain how the study size was arrived at | 4–5 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 4–5 |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | 5 |
| (b) Describe any methods used to examine subgroups and interactions | 5 | ||
| ( | 5 | ||
| ( | 5 | ||
| ( | 5 | ||
|
| |||
| Participants | 13* | (a) Report numbers of individuals at each stage of study—e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed | 7 |
| (b) Give reasons for non-participation at each stage | 4–5 | ||
| (c) Consider use of a flow diagram | – | ||
| Descriptive data | 14* | (a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders | 6 |
| (b) Indicate number of participants with missing data for each variable of interest | – | ||
| Outcome data | 15* | Report numbers of outcome events or summary measures | 6 |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 6 |
| (b) Report category boundaries when continuous variables were categorized | 6 | ||
| (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | 6 | ||
| Other analyses | 17 | Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses | 6 |
|
| |||
| Key results | 18 | Summarize key results with reference to study objectives | 7 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | – |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 7–8 |
| Generalizability | 21 | Discuss the generalizability (external validity) of the study results | 7–8 |
|
| |||
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 09 |
An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org
* Give information separately for exposed and unexposed groups